<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01022723</url>
  </required_header>
  <id_info>
    <org_study_id>CTC_ver2_081109</org_study_id>
    <nct_id>NCT01022723</nct_id>
  </id_info>
  <brief_title>Clinical Validation of a Microfluidic Device for Isolation and Molecular Characterization of Circulating Tumor Cells</brief_title>
  <acronym>CTC</acronym>
  <official_title>Clinical Validation of a Microfluidic Device for Isolation and Molecular Characterization of Circulating Tumor Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Centre, Singapore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Medical Research Council (NMRC), Singapore</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National University, Singapore</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Centre, Singapore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficiency of a microdevice for circulating tumor cells isolation and to
      correlate the circulating titre with response and progression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Validate the clinical use of a mircofluidic device to capture circulating timor cells
           from a broad range of tumor types

        -  Characterize and identify these circulating tumor cells and demostrate cell viability
           with this capture method

        -  Apply this technology in clinically relevant settings and correlate to response to
           treatment and disease progression

        -  Elucidate predictive and pharmacodynamic biomarkers in the context of early phase trials
           of novel therapeutics
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The validation of the clinical use of a microfluidic device to capture circulating tumor cells (CTC) from a broad range of tumor types</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characteristics and viability of the CTC with this capture method</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical application of this capture method with the study of CTC titre correlation to treatment outcome</measure>
    <time_frame>6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study of predictive and pharmacodynamic biomarkers of the CTC in the context of early phase trials of novel therapeutics</measure>
    <time_frame>6 years</time_frame>
  </secondary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">366</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Lung Cancer patients</arm_group_label>
    <description>Lung Cancer (particular focus on non smokers with adenocarcinoma)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with Nasopharyneal carcinoma</arm_group_label>
    <description>Patients with Nasopharyneal carcinoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Breast Cancer patients</arm_group_label>
    <description>Breast cancer patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prostate Cancer patients</arm_group_label>
    <description>Prostate cancer patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Colorectal Cancer patients</arm_group_label>
    <description>Colorectal cancer patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gastric Cancer patients</arm_group_label>
    <description>Gastric cancer patients</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Circulating Tumor Cells
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with the following cancers:

        Lung Cancer Nasopharyneal carcinoma Breast cancer Prostate cancer Colorectal cancer Gastric
        cancer
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with newly diagnosed metastatic disease planned for palliative chemotherapy

          -  Tumor types as specified: non smokers with lung adenocarcinoma, undifferentiated
             EBV-ISH positive nasopharyneal carcinoma, breast cancer, colorectal cancer, prostate
             cancer, gastric cancer

          -  Informed consent given for the purposes of blood sampling for this study

          -  Measurable disease by RECIST criteria of at least 1cm is preferred but not a sine qua
             non for study accrual

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wan-Teck Lim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Centre, Singapore</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lanying Wang, Primary</last_name>
    <phone>+6564368267</phone>
    <email>nctwly@nccs.com.sg</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Cancer Centre</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lim W Teck, Medical</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2009</study_first_submitted>
  <study_first_submitted_qc>November 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2009</study_first_posted>
  <last_update_submitted>December 17, 2017</last_update_submitted>
  <last_update_submitted_qc>December 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Circulating tumor cells</keyword>
  <keyword>metastasis</keyword>
  <keyword>cancer</keyword>
  <keyword>cell isolation</keyword>
  <keyword>mircofludics</keyword>
  <keyword>cell detection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplastic Cells, Circulating</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

